secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sensei Biotherapeutics, Inc. (SNSE)
CIK:        0001829802
Form:       8-K
Filed at:   2025-08-05T23:59:59+00:00
Accession:  0001193125-25-173043
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sensei Biotherapeutics Q2 net loss $4.9M; cash runway into Q2 2026; Phase 1/2 data year-end
--------------------------------------------------------------------------------

- Cash, cash equivalents and marketable securities $28.6M at June 30, 2025 (down from $41.3M at Dec 31, 2024).
- Net loss $4.9M for Q2 2025 vs $7.1M for Q2 2024; R&D expenses decreased to $2.5M from $4.6M.
- Phase 1/2 dose expansion cohort enrollment complete (64 patients); full data including 6-month PFS expected by year-end 2025.
- Data to be presented at ESMO Congress 2025 (Oct 17-21) in a mini oral session.
- Regained Nasdaq compliance after 1-for-20 reverse split effective June 16, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1829802/000119312525173043/0001193125-25-173043-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1829802/000119312525173043/d46736d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-173043

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer